Medtronic Expands Its Portfolio with the Acquisition of Contego Medical for Advanced Carotid Treatments
Medtronic's Strategic Acquisition of Contego Medical
In a significant move to enhance its healthcare offerings, Medtronic (NYSE: MDT), a renowned industry leader in medical technology, announced its intent to acquire Contego Medical, a privately held company specialized in advancements for carotid artery disease and peripheral thrombectomy solutions. This acquisition is poised to bolster Medtronic's strategy of investing in targeted technologies that fortify its established medical franchises.
The acquisition follows a successful U.S. distribution agreement between Medtronic and Contego, announced in January 2025, and will serve to broaden the patient access to innovative carotid and peripheral vascular therapies.
David Moeller, the Senior Vice President and President of Medtronic Peripheral Vascular Health, commented on the acquisition, stating, “This strategic acquisition is a pivotal step in reinforcing our leadership in the treatment of carotid artery disease.” He highlighted the goal of blending Medtronic's extensive clinical expertise with Contego's innovative treatments underpinned by solid clinical data, aiming to establish a dominant position in carotid revascularization.
Understanding Carotid Artery Disease
Carotid artery disease poses a serious risk to patients as the carotid arteries—the primary vessels supplying blood to the brain—can become narrowed or blocked. This complication can lead to strokes, which represent approximately 20% of ischemic stroke cases. Traditional carotid revascularization aims to mitigate this risk; however, concerns persist about embolic debris that can be released during these procedures, which might contribute to further stroke risks.
Contego Medical has emerged as a pioneer in this area, designing solutions intended to address these problems effectively. Their technology integrates embolic protection into the treatment process, mitigating risks associated with traditional methods.
Ravish Sachar, M.D., CEO and founder of Contego Medical, reflected on their mission, stating, “Our goal was to answer the unmet needs in clinical settings by innovating technologies that can enhance patient outcomes while simplifying procedural complexities.” The strengthened partnership with Medtronic marks an exciting chapter for Contego as they work towards delivering forward-thinking solutions.
Innovative Technologies in the Acquisition
The planned acquisition encompasses several key products from Contego, most notably the Neuroguard IEP™ Direct System, recognized for being the first and only transcarotid artery revascularization system with integrated embolic protection. This system demonstrated remarkable results during the recently conducted PERFORMANCE III study, showcasing zero occurrences of strokes, neurological deaths, or cranial nerve injuries within 30 days post-procedure.
Such exceptional findings shed light on the urgent need for innovative treatment options in combating stroke-related disabilities, a sentiment echoed by Linnea Burman, Senior Vice President and President of Medtronic Neurovascular. Burman emphasized the importance of developing technologies that reduce stroke risk and advance patient care through this acquisition.
Furthermore, the acquisition will include Contego's Excipio™ thrombectomy devices, which complement Medtronic’s existing Liberant™ thrombectomy system, further facilitating treatments for various peripheral vascular conditions.
Looking Ahead
Medtronic anticipates finalizing the acquisition in the third quarter of its fiscal year, pending customary closing conditions. Valued at $380 million, this acquisition is projected to have a minimal dilutive effect on Medtronic's adjusted earnings per share for FY27 and FY28, with the potential for a neutral to accretive outcome thereafter.
This acquisition not only signifies a strategic expansion of Medtronic’s technology portfolio but also marks an essential step towards delivering innovative solutions to healthcare providers and patients alike.
As Medtronic continues to push the boundaries of healthcare solutions, the integration of Contego Medical's cutting-edge technologies promises a future where patient care is significantly enhanced, focusing on greater accessibility to revolutionary treatments for carotid artery disease and beyond.
About Medtronic
Medtronic, based in Galway, Ireland, is dedicated to tackling some of the world's most pressing health challenges through innovative solutions. The company's commitment to improving lives reflects its diverse and passionate team, uniting to create groundbreaking technologies.
About Contego Medical
Contego Medical, Inc. specializes in creating cutting-edge solutions that transform complex medical procedures into more simplistic and effective processes, particularly in the treatment of vascular diseases. Their innovative offerings continue to thrive, supported by recognition and investment from top healthcare investors.